Skip to main content
. Author manuscript; available in PMC: 2018 Nov 1.
Published in final edited form as: Am J Transplant. 2017 May 30;17(11):2810–2819. doi: 10.1111/ajt.14328

Figure 6.

Figure 6

Absence of recipient MBL or peri-transplant treatment with C1-INH prevents CIS-induced, CTLA4Ig-resistant rejection. A. Kaplan-Meier survival curves of WT BALB/c allografts subjected to 8h CI and transplanted into CTLA4Ig-treated mbl1−/−/mbl2−/− B6, cfb−/− B6, or WT B6+C1-INH (0.4IU/g, d 0–1, or d 7–8), or WT B6 with C1-INH (0.4IU/g, d 0–1) alone. n=4–6/group. p<0.05 vs cfb−/− B6 8h. Statistics calculated by log-rank (Mantel-cox) test. B. Frequencies of donor-reactive IFNγ-producing spleen cells (ELISPOT) 21d post-transplant (WT B/c allografts subjected to 8h CI transplanted into WT B6 recipients ± C1-INH treatment peri-transplant). *p<0.05, n= 4 animals/condition. **p<0.05 vs. all other groups